ReviewNanomedicine (London, England)2008
Design opportunities for actively targeted nanoparticle vaccines.
Review in Nanomedicine (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Potential Application of Exosomes in Vaccine Development and Delivery.Pharmaceutical research · 2022Review
- Hydrogel nanoparticle degradation influences the activation and survival of primary macrophages.Journal of materials chemistry. B · 2021Article
- Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19.ACS biomaterials science & engineering · 2021Review
- Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy.Frontiers in chemistry · 2020Review
- Spontaneous C-cleavage of a truncated intein as fusion tag to produce tag-free VP1 inclusion body nanoparticle vaccine against CVB3-induced viral myocarditis by the oral route.Microbial cell factories · 2019Article
- Dendritic cell engineering for selective targeting of female reproductive tract cancers.The Indian journal of medical research · 2018Review
- Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.Frontiers in immunology · 2017Review
- Nanotechnology for delivery of peptide nucleic acids (PNAs).Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.Advanced drug delivery reviews · 2016Review
- Multifunctional nanoparticles for cancer immunotherapy.Human vaccines & immunotherapeutics · 2016Review
- Advanced Nanobiomaterials: Vaccines, Diagnosis and Treatment of Infectious Diseases.Molecules (Basel, Switzerland) · 2016Review
- PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.Human vaccines & immunotherapeutics · 2016Review
- Article
- Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Utilization of biodegradable polymeric materials as delivery agents in dermatology.Clinical, cosmetic and investigational dermatology · 2014Review
- Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen.International journal of nanomedicine · 2014Article
- Nanoparticles for localized delivery of hyaluronan oligomers towards regenerative repair of elastic matrix.Acta biomaterialia · 2013Article
- Advances in biomimetic regeneration of elastic matrix structures.Drug delivery and translational research · 2012Article
- Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.Biomaterials · 2012Article
- Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates.Journal of controlled release : official journal of the Controlled Release Society · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Vaccines for many infectious diseases are poorly developed or simply unavailable. There are significant technological and practical design issues that contribute to this problem; thus, a solution to the vaccine problem will require a systematic approach to test the multiple variables that are required to address each of the design challenges. Nanoparticle technology is an attractive methodology for optimizing vaccine development because design variables can be tested individually or in combination. The biology of individual components that constitute an effective vaccine is often well understood and may be integrated into particle design, affording optimal immune responses to specific pathogens. Here, we review technological variables and design parameters associated with creating modular nanoparticle vaccine systems that can be used as vectors to protect against disease. Variables, such as the material and size of the core matrix, surface modification for attaching targeting ligands and routes of administration, are discussed. Optimization of these variables is important for the development of nanoparticle-based vaccine systems against infectious diseases and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.